Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CNS Pharmaceuticals, Inc. (CNSP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CNS Pharmaceuticals is a clinical-stage biopharmaceutical company whose common stock trades on The Nasdaq Stock Market LLC under the symbol CNSP, as noted in its current reports on Form 8-K.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information on CNS Pharmaceuticals’ financial condition, risk factors, and discussion of its clinical-stage pipeline of anti-cancer drug candidates for brain and central nervous system tumors. These periodic reports complement the company’s press releases describing its lead candidate TPI 287, an abeotaxane with initial clinical data suggesting potential to cross the blood-brain barrier and treat CNS tumors.
The filings feed also includes current reports on Form 8-K that document material events. Recent 8-K filings describe a leadership transition in which the company entered into an employment agreement with Rami Levin to serve as Chief Executive Officer and President, the resignation and severance arrangements for former CEO John Climaco, and stockholder-approved changes to the company’s capital structure, including amendments to its articles of incorporation and 2020 Equity Plan.
Investors can also use this page to track proxy materials such as the definitive proxy statement on Schedule 14A, which outlines proposals presented at the annual meeting, including election of directors, auditor ratification, advisory votes on executive compensation, and increases in authorized share capital. Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping users quickly understand complex filings, from governance decisions to equity plan amendments, while retaining the ability to read the full original SEC text.
CNS Pharmaceuticals (CNSP) filed its definitive proxy for the November 17, 2025 annual meeting, to be held virtually at 12:00 p.m. Eastern. Stockholders will vote on seven proposals, including director elections, auditor ratification, advisory votes on executive pay and its frequency, and several capital-structure items.
The key proposal seeks to restore authorized capital to pre–reverse split levels: increasing authorized common stock from 25,000,000 to 300,000,000 and preferred stock from 416,667 to 5,000,000. The company effected a 1-for-12 reverse stock split on July 22, 2025, which proportionally reduced authorized shares; this amendment would raise them back. The proxy states additional shares may be used for future financings, equity incentives, conversions/exercises, acquisitions, and other purposes, and that any such issuance could dilute existing stockholders.
As of the October 10, 2025 record date, 574,580 shares of common stock were outstanding. The board recommends voting FOR all proposals, including amendments to the 2020 Stock Plan and the option to hold the advisory vote on executive compensation every year.
CNS Pharmaceuticals, Inc. (CNSP) filed a preliminary proxy statement describing seven proposals for its 2025 annual meeting. Shareholders will vote to elect six directors to serve until the 2026 annual meeting, to ratify MaloneBailey, LLP as the independent auditor for the year ending December 31, 2025, and to approve non-binding advisory votes on executive compensation and the frequency of such votes. The company proposes a large increase in authorized capital: common stock from 25,000,000 to 300,000,000 shares and preferred stock from 416,667 to 5,000,000 shares, plus amendments to the 2020 Stock Plan to add authorized shares for awards. The filing discloses 574,580 shares outstanding as of October 10, 2025 and a 9.99.9% stake held by Armistice Capital, LLC. Named officers include John M. Climaco (CEO), Christopher S. Downs (CFO), and Sandra L. Silberman (CMO).
CNS Pharmaceuticals, Inc. (CNSP) prospectus supplement excerpts describe the terms and disclosures for offerings of debt and equity securities and related distribution arrangements. The issuer agreed that A.G.P. will act as an underwriter for sales of common stock and will receive underwriting compensation and customary indemnification for liabilities under the Securities Act and the Exchange Act. The supplement lists outstanding equity instruments including 333,956 warrants (weighted average exercise price $238.97), 70 option shares (weighted average exercise price $772,562.06; vesting three to four years), 23 RSUs and 62 shares available under the 2020 Stock Plan. The document highlights extensive risk factors, permitted distribution methods, variety of debt and warrant terms that may be issued, and incorporation by reference of prior filings. It also notes certain disclosure accommodations such as permitting only two years of audited financial statements and reduced disclosure obligations related to Sarbanes-Oxley and executive compensation.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 561,148 shares of CNS Pharmaceuticals common stock, representing 9.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), exercises shared voting and dispositive power over these shares; Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The filing states the Master Fund is the direct holder and that it disclaims beneficial ownership to the extent it cannot vote or dispose of the securities under its investment management agreement.